RU2666356C2 - Новые производные морфолинилантрациклина - Google Patents

Новые производные морфолинилантрациклина Download PDF

Info

Publication number
RU2666356C2
RU2666356C2 RU2015150994A RU2015150994A RU2666356C2 RU 2666356 C2 RU2666356 C2 RU 2666356C2 RU 2015150994 A RU2015150994 A RU 2015150994A RU 2015150994 A RU2015150994 A RU 2015150994A RU 2666356 C2 RU2666356 C2 RU 2666356C2
Authority
RU
Russia
Prior art keywords
formula
compound
defined above
compounds
alkyl
Prior art date
Application number
RU2015150994A
Other languages
English (en)
Russian (ru)
Other versions
RU2015150994A3 (enExample
RU2015150994A (ru
Inventor
Итало Берия
Микеле Карузо
Виттория ЛУПИ
Original Assignee
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. filed Critical НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.
Publication of RU2015150994A publication Critical patent/RU2015150994A/ru
Publication of RU2015150994A3 publication Critical patent/RU2015150994A3/ru
Application granted granted Critical
Publication of RU2666356C2 publication Critical patent/RU2666356C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015150994A 2013-04-29 2014-04-23 Новые производные морфолинилантрациклина RU2666356C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13165707 2013-04-29
EP13165707.4 2013-04-29
PCT/EP2014/058262 WO2014177441A1 (en) 2013-04-29 2014-04-23 New morpholinyl anthracycline derivatives

Publications (3)

Publication Number Publication Date
RU2015150994A RU2015150994A (ru) 2017-06-06
RU2015150994A3 RU2015150994A3 (enExample) 2018-01-24
RU2666356C2 true RU2666356C2 (ru) 2018-09-07

Family

ID=48190306

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015150994A RU2666356C2 (ru) 2013-04-29 2014-04-23 Новые производные морфолинилантрациклина

Country Status (8)

Country Link
US (1) US9828405B2 (enExample)
EP (1) EP2991993B1 (enExample)
JP (1) JP2016517871A (enExample)
CN (1) CN105164138B (enExample)
DK (1) DK2991993T3 (enExample)
ES (1) ES2695162T3 (enExample)
RU (1) RU2666356C2 (enExample)
WO (1) WO2014177441A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2715902C2 (ru) * 2014-11-05 2020-03-04 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Функционализированные производные морфолинилантрациклина

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864221B (zh) * 2018-06-08 2022-04-01 中国科学院上海有机化学研究所 阿克拉霉素类似物及其制法和用途
CN110776501B (zh) * 2019-08-22 2021-04-02 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的药物毒素pnu-159682的制备方法及其中间体
CN115043895A (zh) * 2022-07-15 2022-09-13 戊言医药科技（上海）有限公司 一种pnu-159682及其中间体的制备方法
CN115651043A (zh) * 2022-10-27 2023-01-31 戊言医药科技（上海）有限公司 一种蒽环类毒素衍生物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2247885A (en) * 1990-09-12 1992-03-18 Erba Carlo Spa 13-dihydro-3'-(2-alkoxy-4-morpholinyl)anthracyclines
RU2081878C1 (ru) * 1989-03-13 1997-06-20 Фармиталиа Карло Эрба С.Р.Л. Антрациклин гликозид и способ его получения
WO1998002446A1 (en) * 1996-07-11 1998-01-22 Pharmacia & Upjohn S.P.A. Morpholinyl anthracycline derivatives
EA200400729A1 (ru) * 2003-06-25 2004-12-30 Ле Лаборатуар Сервье НОВЫЕ СОЕДИНЕНИЯ БЕНЗО[α]ПИРАНО[3,2-h]АКРИДИН-7-ОНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803124A (en) 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
GB1511680A (en) * 1975-11-18 1978-05-24 Farmaceutici Italia Daunosaminyl anthracyclinones
US4133877A (en) 1976-07-08 1979-01-09 Societa Farmaceutici Italia S.P.A. Anthracycline ethers and use therefor
NZ224252A (en) * 1987-04-21 1991-09-25 Erba Carlo Spa An anthracycline glycoside and its preparation
GB8804429D0 (en) 1988-02-25 1988-03-23 Erba Carlo Spa New 4-demethyl-4-0-(fluorobenzensulfonyl)anthracycline glycosides
GB2225781A (en) 1988-05-13 1990-06-13 Erba Carlo Spa 10-Noranthracyclines
GB8902709D0 (en) 1989-02-07 1989-03-30 Erba Carlo Spa New 4'-epi-4'-amino anthracyclines
GB8905668D0 (en) * 1989-03-13 1989-04-26 Erba Carlo Spa New 3'-(4-morpholinyl)-and 3'-(2-methoxy-4-morpholinyl)-anthracycline derivatives
EP0434960B1 (en) 1989-12-19 1996-09-18 PHARMACIA S.p.A. Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates
GB2296495B (en) 1994-12-23 1998-04-15 Erba Carlo Spa Anthracycline derivatives
AU2009270988A1 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
EP2646456B1 (en) * 2010-12-02 2015-01-21 Nerviano Medical Sciences S.r.l. Process for the preparation of morpholinyl anthracycline derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2081878C1 (ru) * 1989-03-13 1997-06-20 Фармиталиа Карло Эрба С.Р.Л. Антрациклин гликозид и способ его получения
GB2247885A (en) * 1990-09-12 1992-03-18 Erba Carlo Spa 13-dihydro-3'-(2-alkoxy-4-morpholinyl)anthracyclines
WO1998002446A1 (en) * 1996-07-11 1998-01-22 Pharmacia & Upjohn S.P.A. Morpholinyl anthracycline derivatives
EA200400729A1 (ru) * 2003-06-25 2004-12-30 Ле Лаборатуар Сервье НОВЫЕ СОЕДИНЕНИЯ БЕНЗО[α]ПИРАНО[3,2-h]АКРИДИН-7-ОНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2715902C2 (ru) * 2014-11-05 2020-03-04 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Функционализированные производные морфолинилантрациклина

Also Published As

Publication number Publication date
US9828405B2 (en) 2017-11-28
CN105164138A (zh) 2015-12-16
HK1218646A1 (zh) 2017-03-03
EP2991993B1 (en) 2018-06-06
RU2015150994A (ru) 2017-06-06
DK2991993T3 (en) 2018-07-30
CN105164138B (zh) 2017-11-07
JP2016517871A (ja) 2016-06-20
WO2014177441A1 (en) 2014-11-06
ES2695162T3 (es) 2019-01-02
US20160075730A1 (en) 2016-03-17
EP2991993A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
ES2968669T3 (es) Inhibidores selectivos del inflamasoma NLRP3
US4923986A (en) Derivatives of physiologically active substance K-252
CA2208639C (en) Camptothecin derivatives and its manufacturing method
US9828405B2 (en) Morpholinyl anthracycline derivatives
JP2010215645A (ja) 自然に生じるエクチナサイジン及び関連化合物の合成
JP2022176364A (ja) 複素環化合物
ES2686683T3 (es) Derivados de tieno-indol funcionalizados
EA012295B1 (ru) Конденсированные пирролокарбазолы
CN116375707A (zh) Menin抑制剂及其用途
PT1406907E (pt) Derivados antitumorais de et-743
CN113439084B (zh) 倍癌霉素类似物
JP6785780B2 (ja) 官能基化モルホリニルアントラサイクリン誘導体
AU2017331260B2 (en) Anti-cancer agents and preparation thereof
CN117304198B (zh) 7-位及20-位取代的喜树碱衍生物及其用途
HK1218646B (en) New morpholinyl anthracycline derivatives
JP6570034B2 (ja) 新規なグルタミン酸誘導体およびその用途
CN121910896A (zh) 药物偶联物、药物组合物及其制备方法和用途
Gayler Synthetic studies towards penicisulfuranol B; CH activation borylation of staurosporine; design, synthesis, and evaluation of rapamycin and everolimus analogs; design, synthesis, and evaluation of gemfibrozil analogs.
CN118164994A (zh) 一类喜树碱衍生物及其抗体药物偶联物
KR20250123937A (ko) Ikzf2를 조절하는 스피로사이클로알킬 화합물 및 약학 조성물
JPH0834789A (ja) ピロロインドールカルボン酸エステル誘導体及びその製造方法
HK1235060A1 (en) Functionalized morpholinyl anthracycline derivatives
JPH10195074A (ja) 新規なエリプティシン化合物、それらの製造方法及びそれらを含む医薬組成物
JPH0834788A (ja) ピロロベンゾカルバゾール誘導体及びその製造方法
JPH0834786A (ja) トリフルオロメチルピロロインドール誘導体及びその製造方法